All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $324 | $323 | $283 | $289 | $619 | $993 |
| Cost of Revenue | $209 | $192 | $176 | $185 | $252 | $216 |
| Gross Profit | $115 | $131 | $107 | $104 | $367 | $777 |
| Operating Expenses | ||||||
| Selling & Marketing | $50 | $43 | $36 | $41 | $39 | $24 |
| General & Administrative | $120 | $117 | $88 | $89 | $111 | $51 |
| Research & Development | $57 | $54 | $49 | $41 | $29 | $24 |
| Provision for Doubtful Accounts | $8 | $8 | -$2 | -$1 | $33 | $9 |
| Total Operating Expenses | $238 | $222 | $181 | $300 | $188 | $101 |
| Operating Income | -$122 | -$91 | -$74 | -$196 | $179 | $676 |
| Non-Operating | ||||||
| Net Interest Expense | $30 | $31 | $31 | $21 | $5 | -$0 |
| Other Non-Operating Income (Expense) | $0 | -$10 | -$9 | $0 | $0 | $1 |
| EBT (Earnings Before Tax) | -$92 | -$70 | -$52 | -$174 | $184 | $677 |
| Income Tax Expense | -$7 | -$8 | -$8 | $1 | $42 | $175 |
| Minority Interest | -$1 | -$1 | -$1 | -$7 | -$1 | -$1 |
| Net Income | ||||||
| Net Income | -$84 | -$61 | -$43 | -$168 | $143 | $507 |
| Per Share Data | ||||||
| Revenue Per Share | $11.57 | $10.48 | $9.38 | $9.71 | $19.99 | $32.04 |
| EPS (Basic) | -$2.81 | -$1.97 | -$1.41 | -$5.63 | $4.63 | $16.38 |
| EPS (Diluted) | -$2.81 | -$1.97 | -$1.41 | -$5.63 | $4.63 | $16.38 |
| Weighted Avg Shares (Basic) | 28.0M | 30.8M | 30.2M | 29.8M | 30.1M | 29.4M |
| Weighted Avg Shares (Diluted) | 28.0M | 30.8M | 30.2M | 29.8M | 31.0M | 31.0M |
| Shares Outstanding | 28.0M | 30.8M | 30.2M | 29.8M | 31.0M | 31.0M |
Fulgent Genetics (FLGT) financials: revenue, profit and margins
Fulgent Genetics (FLGT) generated about $324 million in revenue and -$84 million in net income (a -25.8% net margin) over the trailing twelve months, growing at roughly -5.2% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Fulgent Genetics's (FLGT) revenue?+
Fulgent Genetics generated about $324 million in revenue over the trailing twelve months. Revenue has grown at roughly -5.2% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Fulgent Genetics profitable?+
Fulgent Genetics reported about -$84 million in net loss over the trailing twelve months, a net margin of roughly -25.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Fulgent Genetics's profit margins?+
Fulgent Genetics runs a gross margin of about 35.6%, an operating margin of about -37.7%, a net margin of about -25.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Fulgent Genetics growing?+
Fulgent Genetics's revenue has compounded at roughly -5.2% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside FLGT's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 27 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 31 Jul 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Services-Medical Laboratories · Pick stocks to compare with FLGT
Held by ETFs
FLGT is in 17 US ETFs. The largest of them, with FLGT's weight in each:
Vanguard Health Care ETFVHT0.01%of the fund
iShares Russell 2000 Value ETFIWN0.03%of the fund
Schwab Fundamental U.S. Small Company ETFFNDA0.03%of the fund
Avantis U.S. Small Cap Equity ETFAVSC0.02%of the fund
Invesco RAFI US 1500 Small-Mid ETFPRFZ0.03%of the fund
Spot a number that looks wrong? Check it in FLGT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing FLGT
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.